Sequence variation and immunologic cross-reactivity among Babesia bovis merozoite surface antigen 1 proteins from

Tanya Leroith1, Kelly A Brayton, John B Molloy

  • 1Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164-7040, USA. tleroith@vetmed.wsu.edu

Infection and Immunity
|August 23, 2005
PubMed

Insights

Babesia bovis merozoite surface antigen 1 (MSA-1) shows significant sequence variation in Australian isolates, leading to a lack of immune cross-reactivity and vaccine evasion. This highlights challenges in developing effective Babesia bovis vaccines.

Area of Science:

  • Veterinary Parasitology
  • Molecular Immunology
  • Bovine Infectious Diseases

Background:

  • Babesia bovis merozoite surface antigen 1 (MSA-1) is crucial for parasite invasion and a target for antibodies.
  • Antigenic variation in MSA-1 is known between geographical strains, but intra-regional variation and its impact on immunity are unclear.

Purpose of the Study:

  • To assess the sequence variation of Babesia bovis MSA-1 within Australia.
  • To determine the effect of this variation on immunologic cross-reactivity and vaccine efficacy.

Main Methods:

  • Sequencing of the MSA-1 gene from Australian B. bovis vaccine strains and breakthrough isolates.
  • Analysis of sequence identity, hydrophilicity, and hydrophobicity in the extracellular domain.
  • Testing immunologic cross-reactivity using sera from vaccinated and infected cattle.

Main Results:

  • Low sequence identity (19.8-46.7% and 18.7-99%) observed in MSA-1's extracellular region between vaccine and breakthrough isolates.
  • Conserved hydrophilicity/hydrophobicity patterns suggest conserved function despite sequence polymorphism.
  • Sequence variation resulted in a lack of immunologic cross-reactivity, with vaccine sera failing to recognize breakthrough strains.

Conclusions:

  • Babesia bovis isolates evading vaccine-induced immunity possess significantly divergent MSA-1 genes.
  • Sequence differences in MSA-1 lead to a complete loss of cross-reactivity in immunized animals.
  • The observed antigenic variation poses a significant challenge for developing broadly protective B. bovis vaccines.